Skip to main content
Signal8
Launch Terminal

Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRMHealthcare
-1.61%$85.00
AH$85.00+0.00%vs close
Mkt Cap$5.52B
Float51.69M
O/S64.93M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Mirum Pharmaceuticals, Inc. logoNASDAQ:MIRM$85.00-1.61%
Upcoming Catalysts
Phase Distribution
39 lead-sponsored trials·11 active·22 completed
Phase 14
Phase 218
Phase 2/32
Phase 310
Phase 41
Not applicable4
(3 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

    Livmarli Oral Product

    Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis

    Enrollment
    230
    Start
    Sep 2025
    Primary Completion
    Sep 2030est.
    Completion
    Dec 2030est.
    NCT07290257
  • Phase 3
    Completed

    Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

    Cholic Acids

    Infantile Refsum's Disease, Zellweger Syndrome +3

    Enrollment
    85
    Start
    Jan 1992
    Primary Completion
    Dec 2009
    Completion
    Dec 2009
    NCT00007020
  • Phase 3
    Completed

    Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

    Cholic acid

    Inborn Errors of Bile Acid Synthesis

    Enrollment
    16
    Start
    Apr 2010
    Primary Completion
    Aug 2010
    Completion
    Aug 2010
    NCT01115582
  • Phase 3
    Completed

    Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

    Cholic Acid

    Bile Acid Synthesis Defect

    Enrollment
    53
    Start
    Jan 2010
    Primary Completion
    Jul 2016
    Completion
    Jul 2016
    NCT01438411
  • Phase 3
    Withdrawn

    A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

    Maralixibat, Placebo

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    Enrollment
    0
    Start
    Oct 2018est.
    Primary Completion
    Jun 2020est.
    Completion
    Jun 2020est.
    NCT03353454
  • Phase 3
    Completed

    A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)

    Maralixibat

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    Enrollment
    93
    Start
    Jul 2019
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT03905330
  • Phase 3
    Completed

    An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

    Maralixibat

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    Enrollment
    84
    Start
    Jan 2020
    Primary Completion
    Apr 2025
    Completion
    Apr 2025
    NCT04185363
  • Phase 3
    Completed

    Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

    Blinded CDCA 250 mg TID, Placebo

    CTX

    Enrollment
    19
    Start
    Jan 2020
    Primary Completion
    Jul 2023
    Completion
    Oct 2023
    NCT04270682
  • Phase 3
    Active, not recruiting

    Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

    Maralixibat

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    Enrollment
    90
    Start
    Oct 2024
    Primary Completion
    Oct 2026est.
    Completion
    Feb 2027est.
    NCT06553768
  • Phase 3
    Recruiting

    A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

    Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg

    Chronic Hepatitis D Infection

    Enrollment
    172
    Start
    Aug 2025
    Primary Completion
    Jun 2027est.
    Completion
    Sep 2029est.
    NCT07200908
  • Phase 3
    Active, not recruiting

    A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

    Brelovitug 300 mg, Brelovitug 900 mg

    Chronic Hepatitis D Infection

    Enrollment
    80
    Start
    Jan 2026
    Primary Completion
    Aug 2026est.
    Completion
    Jan 2029est.
    NCT07298330
  • Phase 2/3
    Active, not recruiting

    A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

    Brelovitug 300 mg, Brelovitug 900 mg

    Chronic Hepatitis D Infection

    Enrollment
    150
    Start
    Mar 2025
    Primary Completion
    May 2029est.
    Completion
    Sep 2029est.
    NCT06907290
  • Phase 2/3
    Recruiting

    Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

    Brelovitug (BJT-778), Bulevirtide

    Chronic Hepatitis D

    Enrollment
    120
    Start
    Feb 2026
    Primary Completion
    Aug 2027est.
    Completion
    Mar 2029est.
    NCT07454837
  • Phase 2
    Completed

    Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

    LUM001, Placebo

    Alagille Syndrome

    Enrollment
    20
    Start
    Aug 2013
    Primary Completion
    Feb 2015
    Completion
    Mar 2015
    NCT01903460
  • Phase 2
    Completed

    Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

    LUM001, Placebo

    PBC, Primary Biliary Cirrhosis

    Enrollment
    66
    Start
    Aug 2013
    Primary Completion
    Apr 2015
    Completion
    Apr 2015
    NCT01904058
  • Phase 2
    Completed

    An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)

    LUM001 (Maralixibat)

    Alagille Syndrome

    Enrollment
    19
    Start
    Dec 2013
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT02047318
  • Phase 2
    Completed

    Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

    LUM001, Placebo

    Alagille Syndrome

    Enrollment
    37
    Start
    Nov 2014
    Primary Completion
    Nov 2016
    Completion
    Nov 2016
    NCT02057692
  • Phase 2
    Completed

    Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

    LUM001 (Maralixibat)

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    Enrollment
    33
    Start
    Mar 2014
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT02057718
  • Phase 2
    Completed

    Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

    LUM001

    Primary Sclerosing Cholangitis (PSC)

    Enrollment
    27
    Start
    Mar 2014
    Primary Completion
    Feb 2016
    Completion
    Feb 2016
    NCT02061540
  • Phase 2
    Completed

    An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

    LUM001 (Maralixibat)

    Alagille Syndrome

    Enrollment
    34
    Start
    Mar 2015
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT02117713
  • Phase 2
    Completed

    Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

    LUM001 (Maralixibat), Placebo

    Alagille Syndrome

    Enrollment
    31
    Start
    Oct 2014
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT02160782
  • Phase 2
    Withdrawn

    An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

    LUM001

    Primary Biliary Cirrhosis

    Enrollment
    0
    Start
    May 2015
    Primary Completion
    Dec 2017est.
    Completion
    Mar 2018est.
    NCT02321306
  • Phase 2
    Terminated

    Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

    SHP626, Placebo

    Non-Alcoholic Steatohepatitis

    Enrollment
    197
    Start
    Oct 2016
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT02787304
  • Phase 2
    Completed

    MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

    Maralixibat

    Cholestatic Liver Disease

    Enrollment
    52
    Start
    Jan 2020
    Primary Completion
    Sep 2024
    Completion
    Sep 2024
    NCT04168385
  • Phase 2
    Completed

    Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

    Maralixibat

    Biliary Atresia

    Enrollment
    75
    Start
    Jul 2021
    Primary Completion
    Nov 2023
    Completion
    Feb 2024
    NCT04524390

1-25 of 39

Search ClinicalTrials.gov for “Mirum Pharmaceuticals”